183129-85-3

Basic information

• Product Name: 4-(4-Ethyl-phenyl)-butyraldehyde
• Synonyms: 4-(4-Ethyl-phenyl)-butyraldehyde
• CAS NO: 183129-85-3
• Molecular Weight: 176.258
• Mol File: 183129-85-3.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 4-(4-Ethyl-phenyl)-butyraldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-Ethyl-phenyl)-butyraldehyde(183129-85-3)
• EPA Substance Registry System: 4-(4-Ethyl-phenyl)-butyraldehyde(183129-85-3)

Safety Data

• Hazardous Substances Data: 183129-85-3(Hazardous Substances Data)

Upstream product

• 183129-81-9 4-(4-ethylphenyl)butan-1-ol 
• 100-41-4 ethylbenzene 
• 5467-53-8 γ-(p-ethylphenyl)butyric acid 
• 49594-75-4 4-(4-ethylphenyl)-4-oxobutyric acid 

Downstream Products

• 183129-92-2 {2-Amino-5-[2-(4-ethyl-phenyl)-ethyl]-thiophen-3-yl}-(2-chloro-phenyl)-methanone 
• 183130-16-7 5-(2-Chloro-phenyl)-7-[2-(4-ethyl-phenyl)-ethyl]-1,3-dihydro-thieno[2,3-e][1,4]diazepin-2-one 
• 183130-00-9 2-Chloro-N-{3-(2-chloro-benzoyl)-5-[2-(4-ethyl-phenyl)-ethyl]-thiophen-2-yl}-acetamide 
• 183130-08-7 2-Amino-N-{3-(2-chloro-benzoyl)-5-[2-(4-ethyl-phenyl)-ethyl]-thiophen-2-yl}-acetamide 
• 1027988-98-2 [5-(2-Chloro-phenyl)-7-[2-(4-ethyl-phenyl)-ethyl]-1,3-dihydro-thieno[2,3-e][1,4]diazepin-(2Z)-ylidene]-hydrazine 

Relevant articles and documents

Structural optimization of 4-(2-chlorophenyl)-9-methyl-6H-thieno [3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepines as antagonists for platelet activating factor: Pharmacological contribution of substituents at the 2- and 6-positions of a condensed ring system

A series of 4-(2-chlorophenyl)-9-methyl-6H-thieno [3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine derivatives bearing substituents at the 2- and 6-positions were synthesized, and evaluated in vitro for their inhibitory activity on rabbit platelet aggregation induced by platelet activating factor (PAF) and in vivo for their preventing effect on PAF-induced mortality in mice. The length of alkyl or arylalkyl side chain at the 2-position was responsible for enhancing the affinity for the PAF receptor. The simultaneous substitution at both the 2- and 6-positions resulted in a successful separation of the affinity for the PAF receptor from that for the benzodiazepine (BZ) receptor. Thus, (±)-4-(2-chlorophenyl)-2-[2-(4-isobutylphenyl)ethyl]- 6,9-dimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4] diazepine (Y-24180) was confirmed to be a specific antagonist for the PAF receptor and is currently under clinical trials.